Study of Supplement's Antioxidant Properties That Contains Natural Extracts
1 other identifier
interventional
62
0 countries
N/A
Brief Summary
While it is well accepted that a low level of RONS production is necessary to maintain physiological function, too much formation of RONS are believed to participate in biomolecules damage. Damage of lipids, proteins and DNA/RNA, to cellular and tissue level, as a consequence of oxidative stress has been linked to a number of serious diseases, including cancer, cardiovascular diseases (CVDs) such as hypertension and atherosclerosis, neurodegenerative diseases such as Parkinson's disease and Alzheimer's dementias, diabetes and the process of aging. The dietary intake of antioxidants is thought to play a major role in oxidative stress network. Many epidemiologic studies have reported an inverse association between vegetable and fruit consumption with reduced risk of chronic diseases, especially cancer and CVDs. However, although many clinical trials have been conducted with vitamins (E, C or their combinations) their in vivo protective effect remains uncertain. Therefore the possibility that the complex mixture of phytochemicals in foods may contribute to their protecting effects has been raised. In this concept, it is possible multiple compounds to act through complimentary or synergistic mechanisms to present a greater biologic effect than can be achieved by any individual component To investigate this hypothesis, a double-blind, randomized, and placebo-controlled clinical trial was conducted in order to investigate the effects of a multi-micronutrient supplement against oxidative stress in apparently healthy adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable healthy
Started Sep 2013
Longer than P75 for not_applicable healthy
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 23, 2016
CompletedFirst Posted
Study publicly available on registry
July 19, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedJuly 20, 2016
July 1, 2016
1.1 years
May 23, 2016
July 19, 2016
Conditions
Outcome Measures
Primary Outcomes (14)
Change from Baseline of isoprostane levels at 4 weeks
urinary isoprostane
0, 4 weeks
Change from Baseline of isoprostane levels at 8 weeks
urinary isoprostane
0, 8 weeks
Change from Baseline of DNA/RNA damage at 4 weeks
urinary DNA/RNA damage
0, 4 weeks
Change from Baseline of DNA/RNA damage at 8 weeks
urinary DNA/RNA damage
0, 8 weeks
Change from Baseline of protein carbonyls levels at 4 weeks
serum
0, 4 weeks
Change from Baseline of protein carbonyls levels at 8 weeks
serum
0, 8 weeks
Change from Baseline of oxLDL levels at 4 weeks
serum
0, 4 weeks
Change from Baseline of oxLDL levels at 8 weeks
serum
0, 8 weeks
Change from Baseline of TBARS levels at 4 weeks
serum
0, 4 weeks
Change from Baseline of TBARS levels at 8 weeks
serum
0, 8 weeks
Change from Baseline of serum resistant in oxidation at 4 weeks
ex vivo serum oxidation with cupper
0, 4 weeks
Change from Baseline of serum resistant in oxidation at 8 weeks
ex vivo serum oxidation with cupper
0, 8 weeks
Change from Baseline of anti-oxidant enzymes activity at 4 weeks
serum
0, 4 weeks
Change from Baseline of anti-oxidant enzymes activity at 8 weeks
serum
0, 8 weeks
Secondary Outcomes (8)
Change from Baseline of Platelet aggregation against PAF at 4 weeks
0, 4 weeks
Change from Baseline of Platelet aggregation against PAF at 8 weeks
0, 8 weeks
Change from Baseline of Platelet aggregation at against ADP 4 weeks
0, 4 weeks
Change from Baseline of Platelet aggregation against ADP at 8 weeks
0, 8 weeks
Change from Baseline of Platelet aggregation against TRAP at 4 weeks
0, 4 weeks
- +3 more secondary outcomes
Study Arms (2)
Supplement
ACTIVE COMPARATORThe supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
Placebo
PLACEBO COMPARATORA look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
Interventions
80ml Mind Master / day for 8 weeks
Eligibility Criteria
You may qualify if:
- healthy
- BMI: 23-30
You may not qualify if:
- regular use of dietary supplements or medications
- being on slimming or any other special diet
- hypertension
- metabolic or endocrine disease
- gastrointestinal disorders
- recent history of medical or surgical events
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Fragopoulou E, Gavriil L, Argyrou C, Malagaris I, Choleva M, Antonopoulou S, Afxentiou G, Nikolaou E. Suppression of DNA/RNA and protein oxidation by dietary supplement which contains plant extracts and vitamins: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2018 Aug 16;17(1):187. doi: 10.1186/s12944-018-0836-z.
PMID: 30115068DERIVED
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Biological Chemistry
Study Record Dates
First Submitted
May 23, 2016
First Posted
July 19, 2016
Study Start
September 1, 2013
Primary Completion
October 1, 2014
Study Completion
December 1, 2017
Last Updated
July 20, 2016
Record last verified: 2016-07